On October 6, 2025, Invivyd, Inc. announced the U.S. FDA's IND clearance for its pivotal clinical program for VYD2311, an antibody aimed at preventing COVID. This is a significant event from an equity investor's perspective, indicating potential advancements in their clinical development.